A family in Bellevue is seeing life-changing results for their son, thanks to a clinical trial drug. However, getting the drug approved by the FDA has been faced with "technicalities." ...

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

Mother Kelly Stacy asks President Donald Trump to let her sick sons try a medicine that could help them survive.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) and reminds investors ...

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive ...

CAPR IMPORTANT DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 15 Deadline in Securities Class Action ...

FDA leaders under President Donald Trump are moving to abandon a decades-old policy of asking outside experts to review drug applications, a move critics say would shield the agency’s decisions from ...

Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.

EDT Capricor Therapeutics (CAPR) files $300M mixed securities shelf Published first on TheFly – the ultimate source for real-time, ...

Capricor Therapeutics has publicised a statement addressing the US Food and Drug Administration’s (FDA) decision to reject ...

Capricor Therapeutics has publicly released its July response to the FDA's rejection of its Duchenne muscular dystrophy cell therapy deramiocel after the agency included deramiocel in a new batch of ...